The Case for Extended Screening Intervals for People With Diabetes and No or Minimal Retinopathy at Baseline

The article by Modjtahedi et al¹ in this issue of JAMA Ophthalmology is noteworthy because it adds to a growing body of evidence that suggests that extending screening intervals to 2 years for those with no or minimal diabetic retinopathy (DR) at baseline may be safe and appropriate. There is an increasing need for screening intervals to be informed by evidence and tailored to risk, given the aging population and the growing burden of diabetes.